SEC Company Response from Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — May 20, 2019
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: May 20, 2019 · CIK: 0001412486 · Accession: 0001493152-19-007813
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231022
Letter
COCRYSTAL PHARMA, INC.
N. CREEK PARKWAY
BOTHELL, WA 98011
May 20, 2019
Via EDGAR
Division of Corporation Finance
Securities and Exchange Commission
F Street, N.E.
Washington, D. C. 20549
Re: Cocrystal Pharma, Inc.
Registration Statement on Form S-3
File No. 333-231022
Ladies and Gentlemen:
In accordance with Rule 461 promulgated pursuant to the Securities Act of 1933, Cocrystal Pharma, Inc. is hereby requesting that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 9:00 AM on May 22, 2019, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact Brian Bernstein, our legal counsel at (561) 471-3516.
Very
truly yours,
/s/
James Martin
Show Raw Text
CORRESP
1
filename1.htm
COCRYSTAL
PHARMA, INC.
19805
N. CREEK PARKWAY
BOTHELL,
WA 98011
May
20, 2019
Via
EDGAR
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, N.E.
Washington,
D. C. 20549
Re:
Cocrystal
Pharma, Inc.
Registration
Statement on Form S-3
File
No. 333-231022
Ladies
and Gentlemen:
In
accordance with Rule 461 promulgated pursuant to the Securities Act of 1933, Cocrystal Pharma, Inc. is hereby requesting that
the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 9:00
AM on May 22, 2019, or as soon thereafter as is practicable.
If
you have any questions regarding this request, please contact Brian Bernstein, our legal counsel at (561) 471-3516.
Very
truly yours,
/s/
James Martin
James
Martin
Chief
Financial Officer
cc:
Brian
S. Bernstein, Esq.
Michael
D. Harris, Esq.